LIVANOVA PLC
LIVNNASDAQTrading Snapshot
- Day Range
- $80.37 β $81.89
- 52-Week Range
- $48.82 β $85.76
- Volume (shares)
- 36,908
- Avg Volume (shares)
- β
- Shares Outstanding
- 55.1M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $1.39B
- Last Q Revenue
- $391M
- P/E Ratio
- 23.6
- P/S Ratio
- 3.0x
- EPS (TTM)
- $3.38
- Dividend Yield
- β
- Dilution (1yr)
- β0.4%
LIVANOVA PLC
LIVNAbout LIVANOVA PLC
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.